GB2507936A - Methods of inducing anesthesia - Google Patents

Methods of inducing anesthesia Download PDF

Info

Publication number
GB2507936A
GB2507936A GB1404639.5A GB201404639A GB2507936A GB 2507936 A GB2507936 A GB 2507936A GB 201404639 A GB201404639 A GB 201404639A GB 2507936 A GB2507936 A GB 2507936A
Authority
GB
United Kingdom
Prior art keywords
anesthetic
methods
provides methods
inducing anesthesia
selectivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1404639.5A
Other languages
English (en)
Other versions
GB201404639D0 (en
Inventor
Robert J Brosnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of GB201404639D0 publication Critical patent/GB201404639D0/en
Publication of GB2507936A publication Critical patent/GB2507936A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • A61D7/04—Devices for anaesthetising animals by gases or vapours; Inhaling devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/01—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes specially adapted for anaesthetising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GB1404639.5A 2012-07-10 2013-03-14 Methods of inducing anesthesia Withdrawn GB2507936A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261670098P 2012-07-10 2012-07-10
US201261681747P 2012-08-10 2012-08-10
PCT/US2013/031668 WO2014011235A1 (en) 2012-07-10 2013-03-14 Methods of inducing anesthesia

Publications (2)

Publication Number Publication Date
GB201404639D0 GB201404639D0 (en) 2014-04-30
GB2507936A true GB2507936A (en) 2014-05-14

Family

ID=49914505

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1404639.5A Withdrawn GB2507936A (en) 2012-07-10 2013-03-14 Methods of inducing anesthesia

Country Status (12)

Country Link
US (6) US20140018414A1 (enExample)
EP (3) EP4032533A1 (enExample)
JP (4) JP2015525757A (enExample)
KR (4) KR20150036535A (enExample)
CN (3) CN104619319A (enExample)
AU (4) AU2013289204B2 (enExample)
BR (1) BR112015000475A2 (enExample)
CA (2) CA3135005A1 (enExample)
GB (1) GB2507936A (enExample)
IL (3) IL301618A (enExample)
IN (1) IN2015KN00299A (enExample)
WO (2) WO2014011235A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
WO2014011235A1 (en) 2012-07-10 2014-01-16 The Regents Of The University Of California Methods of inducing anesthesia
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
WO2015187918A2 (en) 2014-06-05 2015-12-10 The Regents Of The University Of California Halogenated ether compounds and methods of inducing anesthesia
EP3040061A1 (en) * 2015-01-02 2016-07-06 Fitesa Germany GmbH Nonwoven fabric and process for forming the same
CN105168202A (zh) * 2015-10-09 2015-12-23 烟台毓璜顶医院 一种吸入式复合麻醉维持剂
US10467138B2 (en) * 2015-12-28 2019-11-05 Advanced Micro Devices, Inc. Caching policies for processing units on multiple sockets
JP7307586B2 (ja) * 2019-04-26 2023-07-12 東ソー株式会社 パーフルオロ（２，４－ジメチル－２－フルオロホルミル－１，３－ジオキソラン）の製造方法
CN112638891B (zh) 2018-09-03 2024-12-10 东曹株式会社 三氟丙酮酰氟二聚体及全氟(2,4-二甲基-2-氟甲酰基-1,3-二氧戊环)的制造方法
JP7307587B2 (ja) * 2018-09-03 2023-07-12 東ソー株式会社 ヘキサフルオロプロピレンオキシドへのアルデヒド類付加体、およびトリフルオロピルビン酸フルオリドダイマーの製造方法
WO2020050249A1 (ja) * 2018-09-03 2020-03-12 東ソ－株式会社 ヘキサフルオロプロピレンオキシドへのアルデヒド類付加体、トリフルオロピルビン酸フルオリドダイマーの製造方法およびパーフルオロ（２，４－ジメチル－２－フルオロホルミル－１，３－ジオキソラン）の製造方法
WO2020065492A1 (en) * 2018-09-26 2020-04-02 3M Innovative Properties Company Hydrofluoroethers and methods of using same
WO2020123551A1 (en) * 2018-12-10 2020-06-18 Halo Science LLC Stable formulations of anesthetics and associated dosage forms
WO2021146371A1 (en) * 2020-01-17 2021-07-22 Expanesthetics, Inc. Method of inducing analgesia using a halogenated alcohol
WO2022204459A1 (en) * 2021-03-25 2022-09-29 University Of Florida Research Foundation, Inc. Methods and compositions for treatment of low circulating testosterone conditions
WO2024123878A1 (en) 2022-12-09 2024-06-13 Expanesthetics, Inc. Fluorinated dioxolane compound
US20250025647A1 (en) * 2023-07-18 2025-01-23 Anecare, Llc Reactivation of and restoration of electrical signaling by neurons involved in controlling brain function

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1069639B (de) 1959-11-26 Salline Ludwigshalle A.G., Bad Wimpfen Verfahren zur Herstellung von cyclischen Perfluorkohlcnstoffäthern mit 5- oder 6-gliedrigen Ringen
US2594272A (en) 1948-09-10 1952-04-29 Minnesota Mining & Mfg Cyclic fluoroalkylene oxide compounds
GB718318A (en) 1952-06-24 1954-11-10 Minnesota Mining & Mfg Improvements in or relating to process of preparing cyclic fluoroalkylene oxide compounds and the cyclic fluoroalkylene oxide compounds resulting from said process
ES251349A1 (es) 1958-08-21 1960-01-16 Ludwigshalle Saline PROCEDIMIENTO PARA LA OBTENCIoN DE ÉTERES PERFLUOROCARBoNICOS CiCLICOS CON ANILLOS DE 5 o 6 MIEMBROS
US3187748A (en) 1963-04-29 1965-06-08 Merck And Company Inc Inhalation-actuated aerosol device
US3314850A (en) * 1965-09-17 1967-04-18 Allied Chem 2, 2-bis(trifluoromethyl)-1, 3-dioxolane as inhalation anesthetic
US3476860A (en) 1966-12-08 1969-11-04 Air Reduction Halomethyl fluoroisopropyl ethers as anesthetic agents
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
NL7103057A (enExample) 1970-03-12 1971-09-14
US3683092A (en) 1970-07-31 1972-08-08 Baxter Laboratories Inc Method of anesthesia
JPS4812742B1 (enExample) 1970-08-17 1973-04-23
JPS4927588B1 (enExample) 1970-10-14 1974-07-18
US3749791A (en) * 1971-07-15 1973-07-31 Airco Inc Fluorine or chlorine-substituted 2,2-bis(trifluoromethyl)-1,3-dioxolane anesthetics
NO134730L (enExample) 1971-07-19 1900-01-01
US3749793A (en) * 1971-08-02 1973-07-31 Airco Inc Ether compounds as inhalation anesthetics
US3954893A (en) 1971-08-09 1976-05-04 W. R. Grace & Co. New halogenated cyclobutanes
NL7115894A (enExample) * 1971-08-09 1973-02-13
NL7115893A (enExample) 1971-08-09 1973-02-13
US3870797A (en) 1971-08-09 1975-03-11 Grace W R & Co Anesthetic halogenated cyclobutanes
US3749794A (en) * 1971-08-13 1973-07-31 Airco Inc Ether compounds as inhalation anesthetics
US3897502A (en) 1971-10-22 1975-07-29 Airco Inc Process for making fluorinated ethers
GB1413285A (en) 1971-11-25 1975-11-12 Bespak Industries Ltd Aerosol devices
US4060532A (en) 1972-03-15 1977-11-29 Ici United States Inc. Halogenated dioxolane tranquilizers
GB1448981A (en) 1972-06-09 1976-09-08 Ici Ltd Fluorinated dioxan derivatives
US4017519A (en) 1973-04-05 1977-04-12 Airco, Inc. Fluoro dioxolane anesthetic compounds
US4113435A (en) 1973-07-16 1978-09-12 Massachusetts Institute Of Technology Cryogenically controlled direct fluorination apparatus
JPS514994B2 (enExample) 1974-01-31 1976-02-16
DE2520962A1 (de) 1975-05-12 1976-12-02 Hoechst Ag 1.2.2.2-tetrafluoraethyl-fluormethylaether und verfahren zu dessen herstellung
DE2524956A1 (de) 1975-06-05 1976-12-16 Hoechst Ag 2-hydro-perfluor-n-propyl-fluormethylaether und verfahren zu seiner herstellung
DE2604350A1 (de) * 1975-09-22 1977-03-24 Stanford Research Inst Anaesthetisch wirksame halogen-substituierte 2,2-difluor-1,3-dioxolane und verfahren zur inhalations-anaesthesie
JPS5145594B2 (enExample) 1975-12-10 1976-12-04
JPS5325552A (en) 1976-08-21 1978-03-09 Agency Of Ind Science & Technol Preparation of perfluorotetrahydrofuran derivatives
JPS53124259A (en) 1977-04-06 1978-10-30 Agency Of Ind Science & Technol Preparation of perfluoro (3-methyltetrahydrofran)
JPS5551084A (en) 1978-10-11 1980-04-14 Agency Of Ind Science & Technol Purification of perfluoro(2-alkyltetrahydropyran)
DE2906447A1 (de) * 1979-02-20 1980-09-04 Hoechst Ag Verfahren zur herstellung von 4,5- perfluor-1,3-dioxolanen und neue verbindungen dieser klasse
US4346246A (en) 1979-03-12 1982-08-24 Airco, Inc. Process for adjusting the halogen content of halogenated aliphatic ethers
US4334105A (en) 1979-04-25 1982-06-08 Airco, Inc. Method for the dehalogenation of ethers
JPS56142877A (en) 1980-07-23 1981-11-07 Agency Of Ind Science & Technol Manufacture of perfluoro (3-methyltetrahydrofuran)
US4533741A (en) 1981-11-19 1985-08-06 E. I. Dupont De Nemours And Company 4,5-Dichloro-2,2,4,5,-tetrafluoro-1,3-dioxolane
US4648393A (en) 1984-11-02 1987-03-10 Ackrad Laboratories, Inc. Breath activated medication spray
US4592348A (en) 1984-12-17 1986-06-03 Waters Iv William C Aerosol inhaler
US4803978A (en) 1985-08-09 1989-02-14 Johnson Iv John J Apparatus for actuating an inhaler
US4929317A (en) 1986-12-01 1990-05-29 Tokuyama Soda Kabushiki Kaisha Process for preparation of perfluoro organic compounds
US4762856A (en) 1987-02-02 1988-08-09 Boc, Inc. Anesthetic composition and method of using the same
US4896832A (en) 1987-09-07 1990-01-30 Bespak Plc Dispensing apparatus for metered quantities of pressurised fluid
DE3735467A1 (de) 1987-10-20 1989-05-03 Bayer Ag Verfahren zur herstellung von fluorierten c(pfeil abwaerts)4(pfeil abwaerts)- bis c(pfeil abwaerts)6(pfeil abwaerts)-kohlenwasserstoffen und neue cyclische fluorierte kohlenwasserstoffe, sowie die verwendung von fluorierten c(pfeil abwaerts)4(pfeil abwaerts)- bis c(pfeil abwaerts)6(pfeil abwaerts)-kohlenwasserstoffen als treibgas und arbeitsfluessigkeit fuer waermepumpensysteme
JP2606875B2 (ja) 1988-03-31 1997-05-07 株式会社トクヤマ 有機化合物のフッ素化方法
IT1230873B (it) 1989-06-20 1991-11-08 Ausimont Srl Processo per la preparazione di peraloeteri da peraloolefine e nuovi peraloeteri ottenuti.
US5026801A (en) 1989-09-18 1991-06-25 E. I. Du Pont De Nemours And Company Polyhalodihydrodioxins and polyhalodioxoles
DE69025412T2 (de) 1989-12-11 1996-07-04 Du Pont Teilweise fluorierte verbindungen und polymere
DE4004494A1 (de) 1990-02-14 1991-08-22 Bayer Ag Verfahren zur herstellung von gesaettigten, fluorhaltigen und chlorfreien kohlenwasserstoffen
AU7225891A (en) 1990-03-05 1991-10-10 E.I. Du Pont De Nemours And Company 1,1,2,2,3,3-hexafluorocyclopentane and use thereof in compositions and processes for cleaning
IT1249208B (it) 1990-06-07 1995-02-20 Ausimont Srl Processo per la preparazione di 1,3-diossolani alogenati e nuovi prodotti ottenuti
IT1244708B (it) 1991-02-07 1994-08-08 Ausimont Spa Processo di dealogenazione di 1,3-diossolani
US5268122A (en) 1991-08-28 1993-12-07 E. I. Du Pont De Nemours And Company Gem-dihydropolyfluoroalkanes and monohydropolyfluoroalkenes, processes for their production, and use of gem-dihydropolyfluoroalkanes in cleaning compositions
US5569796A (en) 1992-09-30 1996-10-29 Nippon Zeon Co., Ltd. Process for producing fluorinated saturated hydrocarbon
US5488189A (en) 1993-12-14 1996-01-30 E. I. Du Pont De Nemours And Company Process for fluorinated propanes and pentanes
IT1269517B (it) 1994-05-19 1997-04-01 Ausimont Spa Polimeri e copolimeri fluorurati contenenti strutture cicliche
JP3818395B2 (ja) 1994-06-30 2006-09-06 独立行政法人産業技術総合研究所 弗素化アルケン誘導体及び弗素化アルカン誘導体の製造方法
JP3729281B2 (ja) 1994-11-24 2005-12-21 独立行政法人産業技術総合研究所 弗素化アルケン誘導体および弗素化アルカン誘導体の製造方法
JPH10316597A (ja) 1997-05-15 1998-12-02 Agency Of Ind Science & Technol 弗素化飽和炭化水素
CN1127462C (zh) 1997-12-26 2003-11-12 日本瑞翁株式会社 含－ch2－chf－基团的化合物的制备方法
IT1298257B1 (it) 1998-02-17 1999-12-20 Ausimont Spa Perfluorodiossoli
JP4186253B2 (ja) 1998-03-31 2008-11-26 日本ゼオン株式会社 フッ素化飽和炭化水素の製造方法
JP4120043B2 (ja) 1998-04-01 2008-07-16 日本ゼオン株式会社 フッ素化不飽和炭化水素の製造方法
JP3072083B2 (ja) 1998-11-04 2000-07-31 財団法人地球環境産業技術研究機構 含フッ素ジオキソランおよびその製造方法
DE69929736T2 (de) 1998-11-05 2006-11-02 Central Glass Co., Ltd., Ube Verfahren zur Herstellung von perhalogenierten fünfgliedrigen zyklischen Verbindungen
JP3856076B2 (ja) 1998-11-30 2006-12-13 日本ゼオン株式会社 ヘプタフルオロシクロペンタンの製造方法
JP3794859B2 (ja) 1999-03-01 2006-07-12 セントラル硝子株式会社 パーハロゲン化シクロペンタンの製造方法
JP2001240569A (ja) 2000-02-29 2001-09-04 Nippon Zeon Co Ltd −ｃｈ２−ｃｈｆ−基を有する化合物の製造方法
JP4423414B2 (ja) 2000-02-29 2010-03-03 独立行政法人産業技術総合研究所 ヘプタフルオロシクロペンタンの製造方法
JP4306081B2 (ja) 2000-03-07 2009-07-29 日本ゼオン株式会社 １，１，２，２，３，３，４−ヘプタフルオロシクロペンタンの製造方法およびその製造装置
JP3897081B2 (ja) 2000-03-17 2007-03-22 日本ゼオン株式会社 １−クロロヘプタフルオロシクロペンテンの製造方法
JP4169121B2 (ja) 2001-02-13 2008-10-22 日本ゼオン株式会社 ヘプタフルオロシクロペンタンの製造方法
CA2463999C (en) 2001-10-17 2011-09-27 Minrad Inc. Drug delivery system for conscious sedation
ITMI20030606A1 (it) 2003-03-27 2004-09-28 Solvay Solexis Spa Procedimento per preparare idrofluoroeteri.
US7067468B2 (en) 2003-06-20 2006-06-27 Degroot Richard J Azeotrope compositions containing a fluorocyclopentane
ITMI20071481A1 (it) 2007-07-23 2009-01-24 Milano Politecnico Processo per la sintesi di perfluoroalchileteri
KR20100049663A (ko) 2007-08-27 2010-05-12 와이어쓰 엘엘씨 마취제-절감 효과를 달성하기 위해 ｎｍｄａ 길항제를 사용하는 조성물 및 방법
EP2459182B1 (en) 2009-07-30 2017-09-06 University of Zürich Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
CN101698649B (zh) * 2009-10-22 2012-03-07 李世系 一种用于麻醉的短效催眠镇静的化合物
WO2014011235A1 (en) * 2012-07-10 2014-01-16 The Regents Of The University Of California Methods of inducing anesthesia
WO2015187918A2 (en) 2014-06-05 2015-12-10 The Regents Of The University Of California Halogenated ether compounds and methods of inducing anesthesia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALTOMARE,C. et al., 'Highly water-soluble derivatives of the anesthetic agent propofol: in vitro and in vivo evaluation of cyclic amino acid esters', European Journal of Pharmaceutical Sciences, 2003, Vol.20, pages 17-26. *
BROSNAN, R. et al. ,'Hydrocarbon molar water solubility predicts GABA(A) and NMDA receptor modulation' In:Anesthesiology 2011, American Society of Anesthesiologists Annual Meeting, 2011, A1597. *
INGOLFSSON, H.I.etat.,'Alcohol's effects on lipid bilayer properties' Biophysical Journal, 2011,Vol.101, pages 847-855. *
LIU, Y. et al.,'Role of GABA in the actions of ethanol in rats selectively bred for ethanol sensitivity', Pharmacology Biochemistry and Behavior,1998,Vol. 60, No. 4, pages 793-801. *
LUDVIG, N.et al.,'Histological evidence for drug diffusion across the cerebral meninges into the underlying neocortex in rats', Brain Research, 2008, Vol.1188, pages 228-232. *
MING, Z. et al., 'Differential modulation of GABA- and NMDA-gated currents by ethanol and isoflurane in cultured rat cerebral cortical neurons', Brain Research, 2001, Vol. 920, pages 117-124. *

Also Published As

Publication number Publication date
AU2013289204A1 (en) 2015-02-19
EP2872134A1 (en) 2015-05-20
CA3135005A1 (en) 2014-01-16
IN2015KN00299A (enExample) 2015-06-12
KR20210137252A (ko) 2021-11-17
AU2022200492A1 (en) 2022-02-17
CN104619319A (zh) 2015-05-13
EP3329966B1 (en) 2021-12-22
EP4032533A1 (en) 2022-07-27
AU2013289204B2 (en) 2018-05-10
AU2019275518A1 (en) 2019-12-19
JP2019218397A (ja) 2019-12-26
IL236644B (en) 2020-09-30
US10010525B2 (en) 2018-07-03
IL276761B1 (en) 2023-04-01
CN116585292A (zh) 2023-08-15
JP2018052954A (ja) 2018-04-05
US20220288011A9 (en) 2022-09-15
US20190000793A1 (en) 2019-01-03
US20180116997A1 (en) 2018-05-03
CA2878686A1 (en) 2014-01-16
KR20230078698A (ko) 2023-06-02
KR20150036535A (ko) 2015-04-07
IL301618A (en) 2023-05-01
JP6916542B2 (ja) 2021-08-11
EP2872134A4 (en) 2016-01-27
AU2019275518B2 (en) 2021-10-28
CN108042514A (zh) 2018-05-18
US9757353B2 (en) 2017-09-12
JP6585139B2 (ja) 2019-10-02
IL236644A0 (en) 2015-02-26
US9381185B2 (en) 2016-07-05
US20210322363A1 (en) 2021-10-21
WO2014011235A1 (en) 2014-01-16
BR112015000475A2 (pt) 2017-08-08
JP7427259B2 (ja) 2024-02-05
WO2014011815A2 (en) 2014-01-16
US20150157596A1 (en) 2015-06-11
AU2018202933A1 (en) 2018-05-17
JP2015525757A (ja) 2015-09-07
US20160296496A1 (en) 2016-10-13
IL276761A (en) 2020-10-29
IL276761B2 (en) 2023-08-01
JP2021169487A (ja) 2021-10-28
US20140018414A1 (en) 2014-01-16
GB201404639D0 (en) 2014-04-30
KR20200078684A (ko) 2020-07-01
EP3329966A1 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
GB2507936A (en) Methods of inducing anesthesia
EA201400591A1 (ru) Ингалятор
EP2747813A4 (en) BIOFEEDBACKING DEVICE FOR BREATHING
MX2013012526A (es) Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.
EP2693881A4 (en) SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGUES AS AXL KINASE INHIBITORS
MX349950B (es) Profarmacos de treprostinil enlazados a un portador.
IN2014CN02616A (enExample)
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
MX344473B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
MX2015005858A (es) Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
IL229260A0 (en) Preparations, methods and systems for respiratory administration of two or more active agents
MX2015005735A (es) Moduladores de dihidropirazol de receptor acoplado a la proteona g (gpr40).
MY187718A (en) Pharmaceutical formulations
EA201590272A1 (ru) Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб
MX2015005720A (es) Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
EA201490756A1 (ru) Разагилина цитрамид
IT1403684B1 (it) Macchina per la preparazione di bevande mediante infusione.
MX2013010046A (es) Administracion parenteral de tapentadol.
PH12016502229A1 (en) Process for preparing phosphorus-containing cyanohydrins
BR112014026305A2 (pt) derivado de quinazolidinadiona
MX2014001764A (es) Inhibidor de alfa1-proteinasa para demorar el comienzo o progresion de exacerbaciones pulmonares.
NI201200195A (es) Procedimiento de preparación de la sal de l - arginina de perindoprilo
IN2014DN06964A (enExample)

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)